Insight

Radiotherapy should be recommended for patients with metastatic castration-sensitive Prostate Cancer, summarized by Gustavo Viani

Gustavo Viani/onconews.com.br

Nov 23, 2024, 15:35

Radiotherapy should be recommended for patients with metastatic castration-sensitive Prostate Cancer, summarized by Gustavo Viani

Gustavo Viani, Associate Professor at Hospital das Clínicas, shared an article by Alberto Bossi on LinkedIn:

” Radiotherapy should be recommended for with metastatic castration-sensitive prostate cancer, independently of their metastatic burden.

Objective:
• To evaluate the efficacy and safety of adding to standard of care in with de novo metastatic castration-sensitive prostate cancer (mCSPC), focusing on radiographic progression-free survival (rPFS) and overall survival (OS)

Methods:
• Study Design: Open-label, randomised, phase 3 trial (PEACE-1) with a 2 × 2 factorial
• Participants:
• aged ≥18 years with de novo mCSPC.
• Confirmed by bone scan, CT, or MRI; Eastern Cooperative Oncology Group performance status of 0–1
• Interventions:
• 4 groups:
1. Standard of care (androgen-deprivation therapy with or without docetaxel).
2. Standard of care + abiraterone (oral 1000 mg daily with prednisone).
3. Standard of care + (74 Gy in 37 fractions).
4. Standard of care + abiraterone.
• Endpoints:
• : Radiographic progression-free survival and overall survival.
• Analysis: Intention-to-treat for low-volume disease and overall population.

Results:
• : 1173 enrolled;
• Fu: Median 6.0 years (IQR 5.1–7.0)

Key Findings:
• Adding rPFS in with low-volume disease treated with abiraterone (median 7.5 years vs 4.4 years; HR 0.65; p=0.019).
• No benefit in low-volume not treated with abiraterone (median 2.6 years vs 3.0 years; HR 1.08; p=0.61).
• No significant difference in OS for low-volume disease with (median 7.5 years vs 6.9 years; HR 0.98; p=0.86).
• Adverse events (grade ≥3) 56.1% of without 58.8% of with.”

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Authors: Alberto Bossi, et al.

Radiotherapy should be recommended for patients with metastatic castration-sensitive Prostate Cancer, summarized by Gustavo Viani

Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Insight

OncoDaily

Insight

Radiotherapy should be recommended for patients with metastatic castration-sensitive Prostate Cancer, summarized by Gustavo Viani